Answers are grounded in this paper and cite their sources.
(MRSA) abscess and sacral osteomyelitis. Serial neurologic evaluations showed no evidence of relapse, and magnetic resonance imaging revealed no active demyelination throughout. Although ocrelizumab may have increased susceptibility to infection, multiple coexisting risk factors, including aspiration risk, frailty, immobility, malnutrition, pressure injury, and recent healthcare exposure, complicated causal attribution. After the first two infectious admissions, the next scheduled infusion was withheld; following the osteomyelitis admission, neurology recommended discontinuation, and the patient remained off disease-modifying therapy without documented relapse at the last follow-up. This case underscores the need to reassess long-term therapy according to recent disease activity, cumulative treatment exposure, immunologic monitoring, infection history, functional status, comorbidities, care context, and patient goals. A single case cannot establish age-based or universal discontinuation thresholds; instead, it supports individualized shared decision-making regarding treatment continuation, interval extension, temporary interruption, or discontinuation.
No takes yet. Share an insight, caveat, or question.
Lo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: